Skip to main content
NACFC 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded Session
Recorded Session
Livestreamed Session
Livestreamed Session
Session is Ticketed (Add-on Session through Registration)
Session is Ticketed (Add-on Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF

Henry Danahay

Enterprise Therapeutics

Henry Danahay PhD, is the Head of Biology, Enterprise Therapeutics. He gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group (UK) in 1997. Whilst with Novartis, he worked as an in vitro/in vivo pharmacologist with a specialisation in airway epithelial cell-based drug targets with a focus on cystic fibrosis. Since co-founding Enterprise Therapeutics in 2014, he has worked on developing TMEM16A potentiators and inhaled ENaC blockers for the treatment of CF. ETD001 (ENaC blocker) and ETD002 (GDC-6988) are now in clinical development.

Presentation(s):